Related Experiment Video
Updated: May 11, 2026

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)
Published on: June 20, 2014
Substituted oxadiazoles: a patent review (2010 - 2012)
Afshin Zarghi1, Zahra Hajimahdi
1Shahid Beheshti University of Medical Sciences, School of Pharmacy, Department of Medicinal Chemistry, P.O. Box: 14155-6153, Tehran, Iran. zarghi@sbmu.ac.ir
Introduction:
The oxadiazoles represent a class of five-membered heterocyclic compounds which are of considerable interest in different areas of medicinal chemistry and drug discovery. Oxadiazoles can exist in different regioisomeric forms and employ in various agents with a broad range of biological activities. This review covers the work reported on various biological activities of oxadiazole derivatives from 2010 to 2012.
Areas Covered:
Oxadiazole derivatives attract great attention due to their different kinds of pharmaceutical activities including antiviral, antimicrobial, anticancer, anticonvulsant, antidiabetic and anti-inflammatory activity. This paper provides a general review of oxadiazole derivatives published in international journals and patented between 2010 and 2012.
Expert Opinion:
Oxadiazoles have been used frequently in drug-like molecules as bioisosteres for ester and amide functionalities and displayed numerous prominent pharmacological effects. The broad pharmacological profile of oxadiazole derivatives has attracted the attention of many researchers to explore this scaffold to its multiple potential against several activities. Therefore, oxadiazole motif is likely to be present in other therapeutic molecules in the future.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Phase I Oxidative Reactions: Overview
FDA Approved Drugs: Changes to Approved Drugs
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
